Completion of the AI Ecosystem Through Investment in FuriosaAI, Acquisition of Bagel Labs, and Integration of Ainut
Full-Scale Advancement in AI Healthcare Convergence and Internalization of the Value Chain
AI solutions company Experix is completing a vertically integrated value chain spanning AI semiconductors, digital therapeutics, and platforms, setting its sights on leading the global healthcare market.
On September 19, Experix announced that it is making bold strategic moves to strengthen its AI healthcare value chain. In May, the company, together with its affiliates, invested in FuriosaAI, a leading domestic AI semiconductor company, thereby securing a core infrastructure. In September, Experix acquired Bagel Labs, the world’s first commercialized digital therapeutics company, and established a joint pipeline with Hanmi Pharmaceutical to develop “AI Obesity Digital Convergent Pharmaceuticals.” In the same month, Experix incorporated Ainut, an AI platform company, enabling the company to internalize data processing and clinical interpretation capabilities, and to independently conduct the entire research and development process.
Through these moves, Experix has rapidly completed a value chain that connects AI semiconductors (in collaboration with FuriosaAI), AI data platforms (Ainut), and AI digital therapeutics (Bagel Labs). This goes beyond simple investments and mergers and acquisitions, as it organically links the major stages of the AI healthcare industry to secure differentiated competitiveness.
A representative from Experix stated, “This year’s series of strategic decisions have laid the foundation for our leap from an AI solutions company to a global healthcare leader. Starting with obesity therapeutics, we plan to expand indications and play a leading role in the field of personalized digital therapeutics through collaborations with global pharmaceutical companies and medical institutions.”
Additionally, Experix plans to maximize synergy with its affiliates to strengthen the group’s overall competitiveness. By integrating the development of AI semiconductors, digital therapeutics, and data platforms into a single value chain, the company aims to enhance research efficiency and expand the potential for global joint research and commercialization through partnerships.
Industry experts believe that Experix’s recent actions will not only mark an entry into new business areas, but also accelerate the global market entry of the domestic AI and healthcare industries as a whole. In particular, the “One-Team” system with FuriosaAI, Bagel Labs, and Ainut is expected to provide a foundation for competing with global big tech companies and multinational pharmaceutical firms.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
